Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Alberola

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Sangre|January 1, 1987
[Blood cell counts in parenteral drug addicts]E Aguilar Ligorit, J Guix García, I Ample Guillén, et al.
Lung Cancer (Amsterdam, Netherlands)|March 16, 2000
Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancerJ A Sacristán, T Kennedy-Martin, R Rosell, et al.
Seminars in Oncology|October 1, 1994
A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysisT Le Chevalier, J L Pujol, J Y Douillard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patientsT Le Chevalier, D Brisgand, J Y Douillard, et al.
Tumori|April 30, 1989
p29 protein in breast cancer: relation between estrogen and progesterone receptorsA Artero Morà, A Lluch Hernandez, A Cano Sanchez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancerR Pérez Carrión, V Alberola Candel, F Calabresi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 17, 2008
Circulating tumor cells in breast cancer: methodology and clinical repercussionsJ M Gasent Blesa, V Alberola Candel, E Esteban González, et al.
Medicina Clinica|September 10, 1988
[Syndrome of persistent generalized lymphadenopathies parenteral drug addicts. Clinical, immunological and histopathological study of 18 cases]E Aguilar Ligorit, J Guix García, C Sánchez Fernández de Sevilla, et al.
Revista Clinica Espanola|November 1, 1994
[A randomized study of navelbine compared to navelbine and cisplatin compared to vindesine and cisplatin in the treatment of inoperable non-small-cell lung carcinoma. The results of a European multicenter study including 612 patients]J L González Larriba, V Alberola, P Lianes, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2005
Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLCM De Lena, R Ramlau, O Hansen, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Sangre|January 1, 1987
[Blood cell counts in parenteral drug addicts]E Aguilar Ligorit, J Guix García, I Ample Guillén, et al.
Lung Cancer (Amsterdam, Netherlands)|March 16, 2000
Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancerJ A Sacristán, T Kennedy-Martin, R Rosell, et al.
Seminars in Oncology|October 1, 1994
A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysisT Le Chevalier, J L Pujol, J Y Douillard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patientsT Le Chevalier, D Brisgand, J Y Douillard, et al.
Tumori|April 30, 1989
p29 protein in breast cancer: relation between estrogen and progesterone receptorsA Artero Morà, A Lluch Hernandez, A Cano Sanchez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancerR Pérez Carrión, V Alberola Candel, F Calabresi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 17, 2008
Circulating tumor cells in breast cancer: methodology and clinical repercussionsJ M Gasent Blesa, V Alberola Candel, E Esteban González, et al.
Medicina Clinica|September 10, 1988
[Syndrome of persistent generalized lymphadenopathies parenteral drug addicts. Clinical, immunological and histopathological study of 18 cases]E Aguilar Ligorit, J Guix García, C Sánchez Fernández de Sevilla, et al.
Revista Clinica Espanola|November 1, 1994
[A randomized study of navelbine compared to navelbine and cisplatin compared to vindesine and cisplatin in the treatment of inoperable non-small-cell lung carcinoma. The results of a European multicenter study including 612 patients]J L González Larriba, V Alberola, P Lianes, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2005
Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLCM De Lena, R Ramlau, O Hansen, et al.
Pageof 8